|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
To determine the role of ACC1 in cancer and normal liver cells, ACC1 expression was downregulated in human hepatoma Hep G2 cells and the rat liver cell line BRL 3A using RNA interference technology, which demonstrated that silencing of ACC1 significantly suppressed the cell viability in the two cell lines.
|
30816537 |
2019 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
These studies highlight the importance of DNL and dysregulation of AMPK-mediated ACC phosphorylation in accelerating HCC and the potential of ACC inhibitors for treatment.
|
30244972 |
2019 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
The enhanced lipogenesis in HCCs is characterized by an increased expression of rate-limiting enzyme acetyl-coenzyme A carboxylase alpha (ACCα).
|
26698170 |
2016 |
|
Liver carcinoma
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Two SNPs in ACACA gene were significantly associated with overall survival of HCC patients.
|
25826294 |
2015 |
|
Liver carcinoma
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Although we did not find any significant results in total analysis (all p>0.05), our stratified data showed that SNP rs9912300 in ACLY gene was significantly associated with overall survival of HCC patients with lower AFP level and SNP rs11871275 in ACACA gene was significantly associated with overall survival of HCC patients with higher AFP level.
|
25735330 |
2015 |
|
Colorectal Carcinoma
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
However, haplotype ACAC was only found to be associated with increased risk of CRC.
|
31740231 |
2020 |
|
Colorectal Carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Among 311 patients with CRC [51.5% male, 25.3% black, 18.7% Hispanic, 32.0% Asian, and mean age at diagnosis 58.1 years (SD 10.3)] 61.4% had advanced ACC stage 3-4 CRC at diagnosis.
|
28040840 |
2017 |
|
Heart failure
|
0.310 |
Biomarker
|
disease |
BEFREE |
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
|
29667019 |
2018 |
|
Congestive heart failure
|
0.310 |
Biomarker
|
disease |
BEFREE |
What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
|
29667019 |
2018 |
|
Fatty Liver
|
0.210 |
Biomarker
|
disease |
BEFREE |
Moreover, NI alleviated hepatic steatosis, possibly by significantly interacting with HFD to regulate lipid metabolism genes (including Srebp1c, Acc1, Fasn, Scd1, Cpt1a and Fabp5).
|
29309075 |
2018 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Blood pressure and the new ACC/AHA hypertension guidelines.
|
31521481 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Approximately 17.0% and 40.1% of participants met the respective definitions of hypertension according to Joint National Committee 7 (JNC7) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) Hypertension Guideline.
|
31382808 |
2020 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Impact of the new criteria of the ACC/AHA on the diagnostic prevalence of hypertension.
|
31481243 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ACC is one of the most malignant tumors in salivary gland, and of poor prognosis.
|
28485162 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, our novel series of potent ACC1 inhibitors represent useful orally-available research tools, as well as potential therapeutic agents for cancer and fatty acid related diseases.
|
30879862 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine the role of ACC1 in cancer and normal liver cells, ACC1 expression was downregulated in human hepatoma Hep G2 cells and the rat liver cell line BRL 3A using RNA interference technology, which demonstrated that silencing of ACC1 significantly suppressed the cell viability in the two cell lines.
|
30816537 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, we identified three heterozygous candidate missense variants in known cancer susceptibility genes (BMPR1A, BRIP1, and SRC), three truncating variants in possibly novel cancer genes (CLSPN, SEC24B, SSH2) and four candidate missense variants in ACACA, NR2C2, INPP4A, and DIDO1.
|
30809968 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Baseline prevalence of hypertension under the AHA/ACC 2017 threshold in participants entering the data set between 20 and 30 years of age was 30.7% in white men (n = 549 of 1790), 23.1% in African American men (n = 245 of 1063), 10.2% in white women (n = 210 of 2070), and 12.3% in African American women (n = 171 of 1390).
|
30916719 |
2019 |
|
Hypertensive disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Status of Hypertension in Tehran: Potential impact of the ACC/AHA 2017 and JNC7 Guidelines, 2012-2015.
|
31011156 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Using the adapted ACC/AHA BPM procedure compared to the CHEP BPM procedure led to an increase in the AHT prevalence rate (≥130/80 mm Hg) of 4% (58% vs. 54%).
|
30371728 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
This Kidney Disease Outcomes Quality Initiative (KDOQI) commentary focuses largely on recommendations from the ACC/AHA hypertension guidelines that are pertinent to individuals at risk of chronic kidney disease or with non-dialysis-dependent chronic kidney disease.
|
30905361 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
ACC/AHA 2017 definition of high blood pressure: implications for women with polycystic ovary syndrome.
|
30827526 |
2019 |
|
Hypertensive disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The recently published BP treatment guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) recommend a systolic BP (SBP) and diastolic BP reduction to less than 130 mmHg and less than 80 mmHg, respectively, for all ages, and have also changed the classification of hypertension by changing the term "prehypertension" of the JNC 7 (7th Joint National Committee) guidelines to "stage 1 hypertension".
|
31050695 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The RPPA analysis of CTCcl+ vs. CTCcl- TNBC PDX tumors revealed elevated expression of Bcl2 (false discovery rate (FDR) < 0.0001, fold change (FC) = 3.5) and reduced acetyl coenzyme A carboxylase-1 (ACC1) (FDR = 0.0005, FC = 0.3) in CTCcl+ compared to CTCcl- tumors.
|
31652963 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Consistent with in vitro findings, treatment of CU-ACC1 PDXs with HITOPK032 significantly reduced tumor growth by 5-fold (p<0.01).
|
31325906 |
2019 |